Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter, Randomized, Open-Label, Phase III Trial

NCT07233668 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT07233668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter, Randomized, Open-Label, Phase III Trial
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
February 1, 2029
Enrollment
172 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma ( mrcc)